Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
BACKGROUND
We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti-proliferative action of cannabinoids and the signal transduction triggered by receptor ligation.


METHODS
The human prostate cancer cell lines, namely PC-3, DU-145 and LNCaP, were used for this study. Cell proliferation was measured using MTT proliferation assay, [(3)H]-thymidine incorporation assay and cell-cycle study by flow cytometry. Ceramide quantification was performed using the DAG kinase method. The CB(2) receptor was silenced with specific small interfering RNA, and was blocked pharmacologically with SR 144528. In vivo studies were conducted by the induction of prostate xenograft tumours in nude mice.


RESULTS
We found that the anandamide analogue, R(+)-Methanandamide (MET), as well as JWH-015, a synthetic CB(2) agonist, exerted anti-proliferative effects in PC-3 cells. R(+)-Methanandamide- and JWH-015-induced cell death was rescued by treatment with the CB(2) receptor antagonist, SR 144528. Downregulation of CB(2) expression reversed the effects of JWH-015, confirming the involvement of CB(2) in the pro-apoptotic effect of cannabinoids. Further analysing the mechanism of JWH-015-induced cell growth inhibition, we found that JWH-015 triggered a de novo synthesis of ceramide, which was involved in cannabinoid-induced cell death, insofar as blocking ceramide synthesis with Fumonisin B1 reduced cell death. Signalling pathways activated by JWH-015 included JNK (c-Jun N-terminal kinase) activation and Akt inhibition. In vivo treatment with JWH-015 caused a significant reduction in tumour growth in mice.


CONCLUSIONS
This study defines the involvement of CB(2)-mediated signalling in the in vivo and in vitro growth inhibition of prostate cancer cells and suggests that CB(2) agonists have potential therapeutic interest and deserve to be explored in the management of prostate cancer.
Olea-Herrero
N
N
Department of Biochemistry and Molecular Biology, School of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.
Vara
D
D
Malagarie-Cazenave
S
S
Díaz-Laviada
I
I
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001095:Arachidonic Acids / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002518:Ceramides / Q000096:biosynthesis; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043885:Receptor, Cannabinoid, CB2 / Q000502:physiology*; D015398:Signal Transduction; D023041:Xenograft Model Antitumor Assays
D001095:Arachidonic Acids; D002518:Ceramides; D007211:Indoles; D043885:Receptor, Cannabinoid, CB2; C088155:methanandamide; C402944:JHW 015
Life Sci. 2005 Aug 19;77(14):1723-31
15958274
J Biol Chem. 2006 Dec 22;281(51):39480-91
17068343
Prostate. 2003 Feb 1;54(2):95-102
12497582
Mol Ther. 2009 Mar;17(3):430-8
19107118
Mini Rev Med Chem. 2005 Jan;5(1):97-106
15638794
Cancer Res. 2008 Jan 15;68(2):339-42
18199524
J Clin Invest. 2009 May;119(5):1359-72
19425170
Trends Pharmacol Sci. 2001 Jan;22(1):19-22
11165667
Biochem Pharmacol. 2009 Jan 1;77(1):86-100
18848818
Cancer Res. 2005 Mar 1;65(5):1635-41
15753356
Toxicol Appl Pharmacol. 2008 Sep 15;231(3):282-90
18556036
Nat Rev Mol Cell Biol. 2008 Jul;9(7):532-42
18568041
Recent Pat Anticancer Drug Discov. 2006 Nov;1(3):369-82
18221047
Curr Med Chem. 2006;13(14):1609-16
16787207
Prostate. 2003 Jun 15;56(1):1-12
12746841
J Neuroendocrinol. 2008 May;20 Suppl 1:10-4
18426493
J Urol. 2007 Oct;178(4 Pt 1):1148
17698142
Sci STKE. 2007 Jul 10;2007(394):jc1
17622645
Curr Med Chem. 2008;15(14):1428-43
18537620
Cancer Res. 2006 Jul 1;66(13):6748-55
16818650
Biochim Biophys Acta. 2009 Jan;1792(1):3-13
19022377
Cancer Lett. 2008 Jun 8;264(1):1-10
18353542
Apoptosis. 2007 Nov;12(11):2013-24
17828457
Clin Cancer Res. 2008 Dec 1;14(23):7691-700
19047095
Pharmacol Biochem Behav. 2008 Oct;90(4):501-11
18584858
Life Sci. 2006 Jan 2;78(6):549-63
16109430
Dialogues Clin Neurosci. 2007;9(4):413-30
18286801
Trends Pharmacol Sci. 2007 Jan;28(1):39-45
17141334
FEBS Lett. 1999 Sep 24;458(3):400-4
10570948
Methods Mol Biol. 2008;414:191-220
18175821
Methods Enzymol. 2000;312:22-31
11070860
Cancer Cell. 2006 Apr;9(4):301-12
16616335
Mol Neurobiol. 2007 Aug;36(1):60-7
17952650
Cancer Biol Ther. 2009 Jan;8(1):64-5
19127120
Semin Cancer Biol. 2008 Jun;18(3):176-89
18249558
Mol Pharmacol. 1998 Nov;54(5):834-43
9804618
Cancer Res. 2006 Jul 1;66(13):6615-21
16818634
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31
19285265
Apoptosis. 2006 Jan;11(1):89-99
16374544
Subcell Biochem. 2008;49:413-40
18751921
Adv Exp Med Biol. 2008;630:57-71
18637485
Apoptosis. 2004 Jul;9(4):423-7
15192324
Mol Cell Biol. 2009 Aug;29(16):4431-40
19528225
Nat Rev Cancer. 2003 Oct;3(10):745-55
14570037
Int J Obes (Lond). 2006 Apr;30 Suppl 1:S13-8
16570099
Mini Rev Med Chem. 2005 Jul;5(7):619-30
16026308
Exp Cell Res. 2006 Jul 1;312(11):2121-31
16624285
FEBS Lett. 2003 Dec 18;555(3):561-6
14675774
Br J Pharmacol. 2006 May;148(2):123-35
16501583
Cancer Res. 2001 Aug 1;61(15):5784-9
11479216
Cancer Res. 2008 Mar 15;68(6):1945-52
18339876
Pharmacol Res. 2003 May;47(5):383-92
12676512
Neuroscience. 2005;134(2):567-74
15975726
Biochem J. 2002 Apr 1;363(Pt 1):183-8
11903061
Endocr Relat Cancer. 2008 Jun;15(2):391-408
18508995
Mol Pharmacol. 2006 Nov;70(5):1612-20
16936228